ScreenerHero

JANXJanux Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · januxrx.com
17.39USD-0.74%Mkt Cap: 1.06B $P/E: —

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.06B $
Enterprise Value106.52M $
Revenue (TTM)24.00M $
Gross Profit-99.98M $
Net Income (TTM)-113.63M $
Revenue/Share0.3840 USD
Last Price17.39 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.55
PEG—
EV/EBITDA-0.75
EV/Revenue4.44
P/S44.02
P/B1.14
EPS (TTM)-1.62
EPS (Forward)-2.64
52W Range
12.1223% of range35.34
52W High35.34 USD
52W Low12.12 USD
Profitability
Gross Margin0.00%
Oper. Margin-308.66%
EBITDA Margin0.00%
Profit Margin-1136.25%
ROE-11.88%
ROA-11.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.23M $
CapEx (TTM)1.04M $
FCF Margin-68.30%
FCF Yield-1.54%
Net Debt-949.92M $
Net Debt/EBITDA6.71
Balance Sheet
Debt/Equity0.02
Current Ratio16.35
Quick Ratio16.25
Book Value/Sh15.19 USD
Cash/Share15.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)37.06 USD
Upside (mean)+113.1%
Target Range14.00 USD – 75.00 USD
$14.00+113.1% to mean$75.00
# Analysts16
Ownership
Shares Out.61.14M
Float42.53M
Insiders1.49%
Institutions101.37%
Short Interest
Short Ratio6.6d
Short % Float12.42%
Short % Out.9.70%
Shares Short5.92M
Short (prev mo.)7.11M
Technical
SMA 5015.52 (+12.0%)
SMA 20016.08 (+8.1%)
Beta2.51
S&P 52W Chg18.16%
Avg Vol (30d)698.33K
Avg Vol (10d)710.86K
Technical Indicators
RSI (14)64.9
MACD0.4124
MACD Signal0.2904
MACD Hist.+0.1220
BB Upper17.38 USD
BB Middle15.97 USD
BB Lower14.57 USD
BB Width17.57%
ATR (14)0.6641 USD
Vol Ratio (20d)0.74x